Scope change in vasculitis: the role of monocytes and macrophages in ANCA-associated glomerulonephritis.

Amsterdam UMC0 个研究点目标入组 103 人开始时间: 待定最近更新: 2024年6月11日

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet following general and group-specific criteria: General 1. Age: 18 years and older Group-specific Patients with ANCA-associated glomerulonephritis (AGN) 1. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) 2. Renal involvement attributable to vasculitis 3. History of PR3/MPO positivity as determined by ELISA in the context of routine clinical care. Hemodialysis controls 1. End stage kidney failure (ESRD) requiring hemodialysis Active infection controls 1. Clinical diagnosis: pneumonia (CURB-65 score 2-5, imaging: X-thorax or CT-thorax showing infiltrates) or complicated urine tract infection 2. Admitted to the hospital <48h Nephrectomy controls 1. Patients who undergo a (partial) nephrectomy for treatment of a renal cell carcinoma, who give consent for the use of surplus kidney tissue for research purposes Patients with (suspected) ANCA vasculitis with pulmonary involvement (API) 1. Suspected or diagnosed with ANCA-associated vasculitis 2. (Suspected) pulmonary involvement attributable to vasculitis 3. Patients who undergo a bronchoalveolar lavage (BAL) for diagnostic purposes SLE patients with renal involvement 1. SLE diagnosis according to the 2019 EULAR/ACR Classification Criteria18 2. Renal involvement attributable to SLE 3. History of ANA positivity

•Patients with ANCA-associated glomerulonephritis (AGN) and Patients with (suspected) ANCA vasculitis with pulmonary involvement 1. A history of drug-induced ANCA-associated vasculitis 2. Active infection as shown by microbiological analysis 3. A history of any other auto-immune disease Healthy controls and hemodialysis controls 1. Active infection as shown by microbiological analysis 2. A history of any auto-immune disease 3. Use of immunosuppressive medication Infection controls 1. Other infection than pneumonia/urine tract infection 2. A history of any auto-immune disease 3. Use of immunosuppressive medication SLE patients 1. A history of drug-induced SLE 2. Active infection as shown by microbiological analysis

发起方

Amsterdam UMC